Pharma Mar, S.A. (BME: PHM)

Spain flag Spain · Delayed Price · Currency is EUR
78.50
-2.25 (-2.79%)
Dec 20, 2024, 5:35 PM CET
79.47%
Market Cap 1.38B
Revenue (ttm) 167.00M
Net Income (ttm) 622.00K
Shares Out 17.54M
EPS (ttm) 0.03
PE Ratio 2,213.51
Forward PE 35.70
Dividend 0.65 (0.83%)
Ex-Dividend Date n/a
Volume 90,266
Open 80.35
Previous Close 80.75
Day's Range 76.70 - 80.60
52-Week Range 26.16 - 86.40
Beta 0.20
Analysts n/a
Price Target n/a
Earnings Date Feb 28, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1986
Employees 509
Stock Exchange Madrid Stock Exchange
Ticker Symbol PHM
Full Company Profile

Financial Performance

In 2023, Pharma Mar's revenue was 158.15 million, a decrease of -19.45% compared to the previous year's 196.34 million. Earnings were 1.14 million, a decrease of -97.70%.

Financial Statements

News

Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript

Pharma Mar, S.A. (OTCPK:PHMMF) Q4 2022 Earnings Conference Call March 1, 2023 7:00 AM ET Company Participants Jose Luis - Head, Investor Relations & Capital Markets Maria Luisa de Francia - Chief Fina...

1 year ago - Seeking Alpha

Pharma Mar, S.A. (PHMMF) Management on Q4 2021 Results - Earnings Call Transcript

Pharma Mar, S.A. (PHMMF) Management on Q4 2021 Results - Earnings Call Transcript

3 years ago - Seeking Alpha